Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07465653 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 24, 2026 → Dec 8, 2026
See other at-risk trials from Novartis

Record History

  1. Primary and study completion pushed from Sep 24, 2026 to Dec 8, 2026 Eligibility criteria shortened, about 8 words · Secondary endpoints: details revised at 1 of 3 entries Show 2 more changesShow less
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Study sites: 4 to 6v4
  3. Study sites: 3 to 4 Eligibility criteria revisedv3 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  4. Recruitment opened Trial sites expanded: 0 → 3 locations · Primary and study completion dates: Sep 21, 2026 to Sep 24, 2026 · Start date changed from estimate of Mar 19, 2026 to Mar 18, 2026v2 Show 3 more changesShow less
    • Trial sites expanded: 0 → 3 locations
    • Primary and study completion dates: Sep 21, 2026 to Sep 24, 2026
    • Start date changed from estimate of Mar 19, 2026 to Mar 18, 2026
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Heart Failure
1,871 trials monitored
See 100 trials at risk
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Trial Details
NCT Number NCT07465653
Lead Sponsor Novartis Pharmaceuticals
Conditions Heart Failure With Reduced Ejection Fraction
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov